BeaconLBS now offers Biocept's Target Selector™ testing for liquid biopsy as part of its laboratory management network in the United States SAN DIEGO , July 22, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians
Expands intellectual property to 37 issued patents globally for highly sensitive methods of detecting cancer biomarkers SAN DIEGO , Oct. 3, 2019 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically
More than eight million members gain access to Biocept's suite of blood-based diagnostics through agreement with Illinois' largest health plan, bringing total covered lives to approximately 133 million
Molecular assay provides highly sensitive, quantitative method to identify cancer involving the central nervous system, inform treatment decisions, and monitor therapy response SAN DIEGO --(BUSINESS WIRE)--Apr. 21, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic
Biocept continues to expand its commercial offering for breast cancer and remains the only liquid biopsy provider to offer single-biomarker testing, tumor-specific panels, and circulating tumor cell analysis SAN DIEGO , June 18, 2019 /PRNewswire/ -- Biocept, Inc.
NCI-designated cancer institute with leading molecular pathology lab obtains rights to utilize and commercially offer Biocept's Target Selector™ liquid biopsy services throughout the state of OregonKnight Diagnostic Laboratories to work with Biocept to co-develop highly sensitive, multiplexed assay panels leveraging OHSU's next generation sequencing (NGS) expertise
SAN DIEGO , Dec. 12, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy solutions, today announced that on December 11, 2019 it closed its previously announced underwritten public offering of 24,600,000 shares of its
